Andreas Scorilas
Andreas Scorilas
  • :+30-210-727-4306
  • :+30-210-727-4158

University of Athens
Department of Biochemistry and MolecularBiology, Biochemistry Lab-1570


  1. Postdoctoral training, Clinical Biochemistry - Pathobiology, Department of Pathology and Laboratory Medicine, Mount Sinai Hospital, and Department of Laboratory Medicine and Pathobiology, University of Toronto, Canada. (1998-2002).
  2. Ph.D., Biochemistry - Molecular Biology, "G. Papanicolau" Research Center of Oncology and Medical School, University of Athens. (1992-96)
  3. B.Sc.(Hon), Chemistry, University of Ioannina, Ioannina, Greece (1986-1990)




Research Interest

  • Study of the physiological role and the diagnostic/ prognostic value of novel molecular tumor biomarkers (Kallikreins, DDC, CEAL, SR-A1, BCL2L12).
  • Molecular cloning, characterization and clinical study of newly discovered human genes and miRNAs, which could be used as molecular markers or therapeutic targets.
  • Development of hypersensitive molecular and immunochemical methods.
  • Development of novel molecular methodologies for prediction of chemotherapy response in cancer cells.


Professional Activities:

  Research Records

  • 236 publications in international peer review scientific journals, including publications in top class journals such as Clinical Chemistry, Journal of Clinical Oncology, Nature Medicine, Cancer Research, Clinical Cancer Research etc.
  • Total Impact Factor, Ι.F = 1013 (4.3 / publication)
  • 5900 citations (Scopus, January, 2015)
  • h-Index = 42 (Scopus, January, 2015)
  • 5 Patents
  • 248 publications in proceedings of international conferences.
  • 50 original complete gene entries in NCBI GeneBank
  • 6 Books and 10 Book chapters
  • 63 publications in Greek
  • Coordinator in 20 accomplished national and international research grants

Research Achievements
Discovery, cloning and identification of the following novel cancer-related genes:

  • The novel apoptotic BCL2L12 gene
  • The new carcinoembryonic antigen gene CEAL1 (CEACAM19)
  • The SR-A1 gene (SCAF1)
  • TSKS, AP2A1 etc
  • Characterization and study of the kallikrein gene family members KLK7, KLK11, KLK15
  • Elucidation of the clinical significance of kallikrein genes, L-Dopa decarboxylase (DDC) gene and other cancer-related genes, in several human malignancies.
  • Development of novel bioanalytical methodologies, useful in Biochemistry and Molecular Diagnostics.

Distinctions and Awards
Major Awards and Distinctions

  • Ranked among the top 3 Researchers-Authors in Europe and the top 6 globally- in the field of Biological Tumor Markers (Biomed Experts, 2014).
  • National Academy of Clinical Biochemistry Award, Los Angeles, USA, 2012.
  • E.K. Frey - E. Werle Promotion Prize, International Scientific Award, Munich, Germany, 2009.
  • Guest Editor of 8 Highlight Issues of the Journals: Biological Chemistry, Thrombosis and Haemostasis, Current Chemical Biology, Anti-Cancer Agents in Medicinal Chemistry, International Scholarly Research Notices, Austin Proteomics, and Austin Journal of Molecular and Cellular Biology.
  • "Dionysios Razis" Scientific Award, Athens, Greece, 2009.
  • The World Metal of Freedom, American Biographical Institute, North Carolina, US, 2008.
  • "Greek Society of Men of Letters" Scientific Award, Athens, Greece, 2008.
  • Empeirikeion Grant Award, Athens, Greece, 2007.
  • Elected Fellow of the International Academy of Clinical and Applied Thrombosis/Haemostasis, New York, US, 2004.



Original Research Papers

  1. Rampias T, Vgenopoulou P, Avgeris M, Polyzos A, Stravodimos K, Valavanis C, Scorilas A, Klinakis A. A new tumor suppressor role for the Notch pathway in bladder cancer. Nature Medicine.; 20(10):1199-205, 2014 (IF=28.054).
  2. Samaan S, Khella HW, Girgis A, Scorilas A, Lianidou E, Gabril M, Krylov SN, Jewett M, Bjarnason GA, El-Said H, Yousef GM. miR-210 Is a Prognostic Marker in Clear Cell Renal Cell Carcinoma. J Mol Diagn., 2014 (IF= 3.955).
  3. Papadopoulos EI, Fragoulis EG, Scorilas A. Human l-DOPA decarboxylase mRNA is a target of miR-145: A prediction to validation workflow. Gene; 554(2):174-180. 3, 2014 (IF= 2.082).
  4. Tzovaras A, Kladi-Skandali A, Michaelidou K, Zografos GC, Missitzis I, Ardavanis A, Scorilas A. BCL2L12: A promising molecular prognostic biomarker in breast cancer. Clin Biochem.; 47(18):257-62, 2014 (IF=2.229).
  5. Vakrakou A, Devetzi M, Papachristopoulou G, Malachias A, Scorilas A, Xynopoulos D, Talieri M. Kallikrein-related peptidase 6 (KLK6) expression in the progression of colon adenoma to carcinoma. Biol Chem.; 395(9):1105-17, 2014 (IF =2.689).
  6. Avgeris M, Stravodimos K, Scorilas A. Loss of miR-378 in prostate cancer, a common regulator of KLK2 and KLK4, correlates with aggressive disease phenotype and predicts the short-term relapse of the patients. Biol Chem.; 395(9):1095-104, 2014 (IF =2.689).
  7. Alexopoulou DK, Kontos CK, Christodoulou S, Papadopoulos IN, Scorilas A. KLK11 mRNA expression predicts poor disease-free and overall survival in colorectal adenocarcinoma patients. Biomark Med; 8(5):671-85, 2014 (IF =2.858).
  8. Girgis H, Masui O, White NM, Scorilas A, Rotondo F, Seivwright A, Gabril M, Filter ER, Girgis AH, Bjarnason GA, Jewett MA, Evans A, Al-Haddad S, Siu KM, Yousef GM Lactate dehydrogenase A is a potential prognostic marker in clear cell renal cell carcinoma. Mol Cancer.; 13:101, 2014  (IF=5.397).
  9. Pavlopoulou A, Scorilas A. A comprehensive phylogenetic and structural analysis of the carcinoembryonic antigen (CEA) gene family. Genome Biol Evol; 6(6):1314-26, 2014 (IF=4.532).
  10. Foteinou E, Kontos CK, Giotakis AI, Scorilas A. Low mRNA expression levels of kallikrein-related peptidase 4 (KLK4) predict short-term relapse in patients with laryngeal squamous cell carcinoma. Biol Chem.;395(9):1051-62, 2014 (IF=2.689)
  11. Rampias T, Giagini A, Siolos S, Matsuzaki H, Sasaki CT, Scorilas A, Psyrri A. RAS/ PI3K crosstalk and cetuximab resistance in head and neck squamous cell carcinoma. Clin Cancer Res. 20(11):2933-46, 2014 (I.F= 8.193).
  12. Rapti SM, Kontos CK, Papadopoulos IN, Scorilas A. Enhanced miR-182 transcription is a predictor of poor overall survival in colorectal adenocarcinoma patients. Clin Chem Lab Med. 52(8):1217-27, 2014 (IF=2.955).
  13. White NM, Masui O, Newsted D, Scorilas A, Romaschin AD, Bjarnason GA, Siu KW, Yousef GM. Galectin-1 has potential prognostic significance and is implicated in clear cell renal cell carcinoma progression through the HIF/mTOR signaling axis. Br J Cancer; 110(5):1250-9, 2014 (IF= 4.817).
  14. Christodoulou S, Alexopoulou DK, Kontos CK, Scorilas A, Papadopoulos IN. Kallikrein-related peptidase-6 (KLK6) mRNA expression is an independent prognostic tissue biomarker of poor disease-free and overall survival in colorectal adenocarcinoma. Tumour Biol; 35(5):4673-85, 2014 (IF=2.840).
  15. Theodorou M, Speletas M, Mamara A, Papachristopoulou G, Lazou V, Scorilas A, Katsantoni E. Identification of a STAT5 target gene, Dpf3, provides novel insights in chronic lymphocytic leukemia. PLoS One. Oct 14; 8(10):e76155, 2013 (IF=3.534).
  16. Koumandou VL, Scorilas A. Evolution of the plasma and tissue kallikreins, and their alternative splicing isoforms. PLoS One; 8(7):e680742013, 2013 (IF=3.534).
  17. Florou D, Patsis C, Ardavanis A, Scorilas A. Effect of doxorubicin, oxaliplatin and methotrexate administration on the transcriptional activity of BCL-2 family gene members in stomach cancer cells. Cancer Biol Ther; 14(7):587-96, 2013 (IF= 3.630).
  18. Foutadakis S, Avgeris M, Tokas T, Stravodimos K, Scorilas A. Increased BCL2L12 expression predicts the short-term relapse of patients with TaT1 bladder cancer following transurethral resection of bladder tumors. Urol Oncol; 32(1):39.e29-36, 2013; (IF= 3.363).
  19. Kontos CK, Fendri A, Khabir A, Mokdad-Gargouri R, Scorilas A. Quantitative expression analysis and prognostic significance of the BCL2-associated X gene in nasopharyngeal carcinoma: a retrospective cohort study. BMC Cancer.; 13:293, 2013 (IF = 3.319).
  20. Avgeris M, Stravodimos K, Fragoulis EG, Scorilas A. The loss of the tumour-suppressor miR-145 results in the shorter disease-free survival of prostate cancer patients. Br J Cancer;108(12):2573-81, 2013 (IF= 4.817).
  21. Mavridis K, Stravodimos K, Scorilas A. Quantified KLK15 Gene Expression Levels Discriminate Prostate Cancer From Benign Tumors and Constitute a Novel Independent Predictor of Disease Progression. Prostate;73(11):1191-201, 2013 (I.F= 3.566).
  22. Michaelidou K, Tzovaras A, Missitzis I, Ardavanis A, Scorilas A. The expression of the CEACAM19 gene, a novel member of the CEA family, is associated with breast cancer progression. Int J Oncol.;42(5):1770-7, 2013 (IF= 2.773).
  23. Alexopoulou DK, Papadopoulos IN, Scorilas A. Clinical significance of kallikrein-related peptidase (KLK10) mRNA expression in colorectal  cancer.Clin Biochem; 46(15):1453-61, 2013 (IF = 2.229).
  24. Mavridis K, Stravodimos K, Scorilas A. Down-regulation and prognostic significance of microRNA 224 (miR-224) expression in prostate cancer. Clin Chem, 59(1):261-9, 2013 (I.F= 7.768).
  25. Korbakis D, Fragoulis EG, Scorilas A. Quantification and study of the L-DOPA decarboxylase expression in gastric adenocarcinoma cells treated with chemotherapeutic substances. Anti-Cancer Drugs, 24(3):291-9, 2013 (I.F= 1.891).
  26. Papachristopoulou G, Talieri M, Scorilas A. Significant alterations in the expression pattern of kallikrein-related peptidase genes KLK4, KLK5 and KLK14 after treatment of breast cancer cells with the chemotherapeutic agents epirubicin, docetaxel and methotrexate. Tumour Biol,  34(1):369-78, 2013 (IF=2.840).
  27. Karan-Djurasevic T, Palibrk V, Zukic B, Spasovski V, Glumac I, Colovic M, Colovic N, Jurisic V, Scorilas A, Pavlovic S, Tosic N. Expression of Bcl2L12 in chronic lymphocytic leukemia patients: association with clinical and molecular prognostic markers. Med Oncol. 30(1):405, 2013 (IF=2.058).
  28. Lichner Z, Scorilas A, White NMA, Girgis AH, Rotstein L, Wiegand KC , Latif A, Chow C,   Huntsman D, Yousef GM. The Chromatin Remodeling Gene, ARID1A is a New Prognostic Marker in Clear Cell Renal Cell Carcinoma. Am J Pathol, 2013 (I.F= 4.602).
  29. Florou D, Papadopoulos IN, Fragoulis EG, Scorilas A. L-Dopa decarboxylase (DDC) constitutes an emerging biomarker in predicting patients' survival with stomach adenocarcinomas.J Cancer Res Clin Oncol, 139(2):297-306, 2013. (IF = 3.009).
  30. Devetzi M, Trangas T, Scorilas A, Xynopoulos D, Talieri M. Parallel overexpression and clinical significance of Kallikrein-related peptidases 7 and 14 (KLK7 & KLK14) in colon cancer. Thromb Haemost, 109(2), 2012. (I.F= 5.760).
  31. Kontos CK, Chantzis D, Papadopoulos IN, Scorilas A. Kallikrein-related peptidase 4 (KLK4) mRNA predicts short-term relapse in colorectal adenocarcinoma patients. Cancer Lett.; 330(1):106-122, 2013  (I.F=5.016).
  32. Geomela PA, Kontos CK, Yiotakis I, Fragoulis EG, Scorilas A. L-DOPA decarboxylase mRNA expression is associated with tumor stage and size in head and neck squamous cell carcinoma: a retrospective cohort study. title="BMC cancer.">BMC Cancer, 20,12(1):484, 2012 (IF = 3.319).
  33. Florou D, Mavridis K, Scorilas A. The kallikrein-related peptidase 13 (KLK13) gene is substantially up-regulated after exposure of gastric cancer cells to antineoplastic agents. Tumour Biol, 33(6):2069-782012 (IF=2.840).
  34. Patsis C, Glyka V, Yiotakis I, Fragoulis EG, Scorilas A. l-DOPA Decarboxylase (DDC) Expression Status as a Novel Molecular Tumor Marker for Diagnostic and Prognostic Purposes in Laryngeal Cancer. Transl Oncol, 5(4):288-96, 2012 (IF=2.558).
  35. Geomela PA, Kontos CK, Yiotakis I, Scorilas A. Quantitative expression analysis of the apoptosis-related gene, BCL2L12, in head and neck squamous cell carcinoma. J Oral Pathol Med, 2012 (IF=1.870).
  36. Thomadaki H, Floros KV, Pavlovic S, Tosic N, Gourgiotis D, Colovic M, Scorilas A. Overexpression of the novel member of the BCL2 gene family, BCL2L12, is associated with the disease outcome in patients with acute myeloid leukemia.Clin Biochem, 45(16-17):1362-7, 2012 (IF=2.229).
  37. Kontos CK, Scorilas A. Molecular cloning of novel alternatively spliced variants of BCL2L12, a new member of the BCL2 gene family, and their expression analysis in cancer cells. Gene, 505(1):153-66, 2012 (IF=2.082).
  38. Faragalla H, Youssef YM, Scorilas A, Khalil B, White NM, Mejia-Guerrero S, Khella H, Jewett MA, Evans A, Lichner Z, Bjarnason G, Sugar L, Attalah MI, Yousef GM. The clinical utility of miR-21 as a diagnostic and prognostic marker for renal cell carcinoma. J Mol Diagn, 14(4):385-92, 2012 (IF=3.955).
  39. Koutalellis G, Stravodimos K, Avgeris M, Mavridis K, Scorilas A, Lazaris A, Constantinides C. L-dopa decarboxylase (DDC) gene expression is related to outcome in patients with prostate cancer. BJU Int, 110(6 Pt B):267-73, 2012 (IF=3.130).
  40. Thanopoulou E, Kotzamanis G, Pateras IS, Ziras N, Papalambros A, Mariolis-Sapsakos T, Sigala F, Johnson E, Kotsinas A, Scorilas A, Gorgoulis VG.The single nucleotide polymorphism g.1548A >G (K469E) of the ICAM-1 gene is associated with worse prognosis in non-small cell lung cancer. Tumour Biol, 33(5):1429-36, 2012 (IF=2.840).
  41. Talieri M, Zoma M, Devetzi M, Scorilas A, Ardavanis A.Kallikrein-related peptidase 6 (KLK6)gene expression in intracranial tumors.Tumour Biol, 33(5):1375-83, 2012 (IF=2.840).
  42. Petraki C, Youssef YM, Dubinski W, Lichner Z, Scorilas A, Pasic MD, Komborozos V, Khalil B, Streutker C, Diamandis EP, Yousef GM. Evaluation and prognostic significance of human tissue kallikrein-related peptidase 10 (KLK10) in colorectal cancer. Tumour Biol, 33(4):1209-14, 2012 (IF=2.840).
  43. Patsis C, Yiotakis I, Scorilas A. Diagnostic and prognostic significance of human kallikrein 11 (KLK11) mRNA expression levels in patients with laryngeal cancer. Clin Biochem, 45(9):623-30, 2012 (IF=2.229).
  44. Evangelou I, Petraki C, Msaouel P, Scorilas A, Sdrolia E, Padazi G, Koborozos V, Koutsilieris M. Immunohistochemical expression of somatostatin receptor subtypes 2 and 5 in colorectal cancer. Eur J Clin Invest, 42(7):777-83, 2012 (IF= 2.834).
  45. Talieri M, Devetzi M, Scorilas A, Pappa E, Tsapralis N, Missitzis I, Ardavanis A. Human kallikrein-related peptidase 12 (KLK12) splice variants expression in breast cancer and their clinical impact. Tumour Biol, 33(4):1075-84, 2012 (IF= 2.840).
  46. Iakovlev VV, Gabril M, Dubinski W, Scorilas A, Youssef YM et al.. Microvascular density as an independent predictor of clinical outcome in renal cell carcinoma: an automated image analysis study. Lab Invest, 92(1):46-56, 2012 (IF=3.828).
  47. Petraki C, Dubinski W, Scorilas A, Saleh C, Pasic MD, Komborozos V, Khalil B, Gabril MY, Streutker C, Diamandis EP, Yousef GM. Evaluation and prognostic significance of human tissue kallikrein-related peptidase 6 (KLK6) in colorectal cancer. Pathol Res Pract, 208(2):104-8, 2012 (IF=1.562).
  48. Korbakis D, Scorilas A. Quantitative expression analysis of the apoptosis-related genes BCL2, BAX and BCL2L12 in gastric adenocarcinoma cells following treatment with the anticancer drugs cisplatin, etoposide and taxol. Tumour Biol, 33(3):865-75, 2012 (IF=2.840).
  49. Avgeris M, Stravodimos K, Scorilas A. Kallikrein-related peptidase 4 gene (KLK4) in prostate tumors: Quantitative expression analysis and evaluation of its clinical significance. Prostate, 71(16):1780-9, 2011 (I.F= 3.566).
  50. Talieri M, Alexopoulou DK, Scorilas A, Kypraios D, Arnogiannaki N, Devetzi M, Patsavela M, Xynopoulos D Expression analysis and clinical evaluation of kallikrein-related peptidase 10 (KLK10) in colorectal cancer. Tumour Biol, 32(4):737-44, 2011. (I.F=2.840).
  51. Papageorgiou SG, Kontos CK, Pappa V, Thomadaki H, Kontsioti F, Dervenoulas J, Papageorgiou E, Economopoulos T, Scorilas A. The Novel Member of the BCL2 Gene Family, BCL2L12, Is Substantially Elevated in Chronic Lymphocytic Leukemia Patients, Supporting Its Value As a Significant Biomarker. Oncologist, 16(9):1280-91, 2011 (IF=4.540).
  52. Dubinski W, Gabril M, Iakovlev VV, Scorilas A, Youssef YM et al. Assessment of the prognostic significance of endoglin (CD105) in clear cell renal cell carcinoma using automated image analysis. Hum Pathol, 43(7):1037-43, 2011 (IF=2.806).
  53. Talieri M, Devetzi M, Scorilas A, Prezas P, Ardavanis A, Apostolaki A, Karameris A. Evaluation of kallikrein-related peptidase 5 expression and its significance for breast cancer patients: association with kallikrein-related peptidase 7 expression. Anticancer Res, 31(9):3093-100, 2011 (IF=1.872).
  54. Avgeris M, Papachristopoulou G, Polychronis A, Scorilas A. Down-regulation of kallikrein-related peptidase 5 (KLK5) expression in breast cancer patients: a biomarker for the differential diagnosis of breast lesions. Clin Proteomics, 31,8(1):5, 2011. (New Journal).
  55. Mathioudaki K, Scorilas A, Ardavanis A, Lymberi P, Tsiambas E, Devetzi M, Apostolaki A, Talieri M. Clinical evaluation of PRMT1 gene expression in breast cancer. Tumour Biol, 32(3):575-82, 2011 (I.F=2.840).
  56. Jamaspishvili T, Scorilas A, Kral M, Khomeriki I, Kurfurstova D, Kolar Z, Bouchal J. Immunohistochemical localization and analysis of kallikrein-related peptidase 7 and 11 expression in paired cancer and benign foci in prostate cancer patients. Neoplasma, 58(4):298-303, 2011 (IF=1.642).
  57. Xinopoulos D, Bassioukas SP, Kypreos D, Korkolis D, Scorilas A, Mavridis K, Dimitroulopoulos D, Paraskevas E.Pancreatic duct guidewire placement for biliary cannulation in a single-session therapeutic ERCP. World J Gastroenterol, 17(15):1989-95, 2011 (IF= 2.433).
  58. Fendri A, Kontos CK, Khabir A, Mokdad-Gargouri R, Scorilas A. BCL2L12 is a Novel Biomarker for the Prediction of Short-term Relapse in Nasopharyngeal Carcinoma. Mol Med.,17(3-4):163-71, 2011 (I.F= 4.824).
  59. Thomadaki H, Lymberopoulou-Karaliota A, Maniatakou A, Scorilas A. Synthesis, spectroscopic study and anticancer activity of a water-soluble Nb(V) peroxo complex. J Inorg Biochem, 105(2):155-63, 2011 (I.F= 3.274).
  60. Dorn J, Harbeck N, Kates R, Gkazepis A, Scorilas A, Soosaipillai A, Diamandis E, Kiechle M, Schmalfeldt B, Schmitt M. Impact of expression differences of kallikrein-related peptidases and of uPA and PAI-1 between primary tumor and omentum metastasis in advanced ovarian cancer. Ann Oncol, 22(4):877-83, 2011 (I.F= 6.578).
  61. Papachristopoulou G, Avgeris M, Charlaftis A, Scorilas A. Quantitative expression analysis and study of the novel human kallikrein-related peptidase 14 gene (KLK14) in malignant and benign breast tissues. Thromb Haemost, 105(1):131-7, 2011 (I.F= 5.760).
  62. Xinopoulos D, Kypreos D, Bassioukas SP, Korkolis D, Mavridis K, Scorilas A, Dimitroulopoulos D, Loukou A, Paraskevas E. Comparative study of balloon and metal olive dilators for endoscopic management of benign anastomotic rectal strictures: clinical and cost-effectiveness outcomes. Surg Endosc, 25(3):756-63, 2010 (I.F=3.413).
  63. Kontos CK, Papadopoulos IN, Fragoulis EG, Scorilas A. Quantitative expression analysis and prognostic significance of L-DOPA decarboxylase in colorectal adenocarcinoma. Br J Cancer. 102(9):1384-90, 2010 (IF= 4.817).
  64. Mavridis K, Avgeris M., Koutalellis G, Stravodimos K, Scorilas A. Expression analysis and study of the KLK15 mRNA splice variants in prostate cancer and benign prostatic hyperplasia Cancer Sci, 101 (3):693 – 699, 2010 (IF= 3.534)
  65. Psyrri A, Papageorgiou S, Liakata E, Scorilas A, Rontogianni D, Kontos CK, Argyriou Pectasides D, Pappa V, Kolialexi A, Economopoulos T. Phosphatidylinositol 3'-kinase catalytic subunit {alpha} gene amplification contributes to the pathogenesis of mantle cell lymphoma. Clin Cancer Res, 391(4):467-74. 2010 (I.F= 8.193).
  66. Mavridis K, Talieri M, Scorilas A. KLK5 gene expression is severely upregulated in androgen independent prostate cancer cells after treatment with the chemotherapeutic agents docetaxel and mitoxantrone. Biol Chem, 391(4):467-74., 2010 (IF=2.689).
  67. Florou D, Papadopoulos IN, Scorilas A. Molecular analysis and prognostic impact of the novel apoptotic gene BCL2L12 in gastric cancer. Biochem Biophys Res Commun, 391(1):214-8, 2010 (IF=2.281).
  68. Fendri A, Kontos CK, Khabir A, Mokdad-Gargouri R, Ardavanis A, Scorilas A. Quantitative analysis of BCL2 mRNA expression in nasopharyngeal carcinoma: an unfavorable and independent prognostic factor. Tumour Biol, 31(5):391-9, 2010 (IF= 2.840).
  69. Konstantoudakis G, Florou D, Mavridis K, Papadopoulos IN, Scorilas A. Kallikrein-related peptidase 13 (KLK13) gene expressional status contributes significantly in the prognosis of primary gastric carcinomas. Clin Biochem, 43(15):1205-11, 2010 (I.F=2.229).
  70. Chow TF, Mankaruos M, Scorilas A, Youssef Y, Girgis A, Mossad S, Metias S, Rofael Y, Honey RJ, Stewart R, Pace KT, Yousef GM. The miR-17-92 Cluster is Over Expressed in and Has an Oncogenic Effect on Renal Cell Carcinoma. J Urol, 183(2):743-51, 2010 (I.F=3.753).
  71. Korbakis D, Gregorakis AK, Scorilas A. Quantitative analysis of human Kallikrein 5 (KLK5) expression in prostate needle biopsies: An independent cancer biomarker. Clin Chem, 55(5): 904-13, 2009 (I.F= 7.768).
  72. Siu KW, DeSouza LV, Scorilas A, Romaschin AD, Honey RJ, Stewart R, Pace K, Youssef Y, Chow TF, Yousef GM. Differential protein expressions in renal cell carcinoma: new biomarker discovery by mass spectrometry. J Proteome Res, (8):3797-807, 2009 (I.F= 5.001).
  73. Korbakis D, Scorilas A. Treatment of gastric cancer cells with 5-fluorouracil/leucovorin and irinotecan induces distinct alterations in the mRNA expression of the apoptosis-related genes, including the novel gene BCL2L12.Tumour Biol, 30(2):100-7, 2009 (I.F=2.840).
  74. Talieri M, Mathioudaki K, Prezas P, Alexopoulou DK, Diamandis EP, Xynopoulos D, Ardavanis A, Arnogiannaki N, Scorilas A. Clinical significance of kallikrein-related peptidase 7 (KLK7) in colorectal cancer. Thromb Haemost, 101(4):741-7, 2009 (I.F= 5.760).
  75. Thomadaki H, Floros KV, Scorilas A. Molecular response of HL-60 cells to mitotic inhibitors vincristine and taxol visualized with apoptosis-related gene expressions, including the new member BCL2L12. Ann N Y Acad Sci, 1171:276-83, 2009 (I.F= 4.313).
  76. Theophanous E, Petraki C, Scorilas A, Komborozos V, Veloudis G, Varga JL, Zarandi M, Schally AV, Koutsilieris M. The immunohistochemical expression of growth hormone-releasing hormone receptor splice variant 1 is a favorable prognostic marker in colorectal cancer. Mol Med, 15(7-8):242-7, 2009 (I.F= 4.824).
  77. Emami N, Scorilas A, Soosaipillai A, Earle T, Mullen B, Diamandis EP. Association between kallikrein-related peptidases (KLKs) and macroscopic indicators of semen analysis: their relation to sperm motility. Biol Chem, 390(9):921-9., 2009 (I.F= 2.689).
  78. Talieri M, Li L, Zheng Y, Alexopoulou DK, Soosaipillai A, Scorilas A, Xynopoulos D, Diamandis EP. The use of kallikrein-related peptidases as adjuvant prognostic markers in colorectal cancer. Br J Cancer, 100(10):1659-65, 2009 (IF= 4.817).
  79. Kountourakis P, Psyrri A, Scorilas A, Markakis S, Kowalski D, Camp RL, Diamandis EP, Dimopoulos MA. Expression and prognostic significance of kallikrein-related peptidase 8 protein levels in advanced ovarian cancer by using automated quantitative analysis. Thromb Haemostasis, 101(3):541-6, 2009 (I.F=5.760).
  80. Papachristopoulou G, Avgeris M, Scorilas A.Expression analysis and study of KLK4 in benign and malignant breast tumours. Thromb Haemostasis, 101 (2):381-7, 2009 (I.F=5.760).
  81. Thomadaki H, Mavridis K, Talieri M, Scorilas A. Treatment of PC3 prostate cancer cells with mitoxantrone, etoposide, doxorubicin and carboplatin induces distinct alterations in the expression of kallikreins 5 and 11. Thromb Haemostasis, 101(2):373-80, 2009 (I.F=5.760).
  82. Devetzi M, Scorilas A, Tsiambas E, Sameni M, Fotiou S, Sloane BF, Talieri M. Cathepsin B protein levels in endometrial cancer: Potential value as a tumour biomarker. Gynecol Oncol, 112(3):531-6, 2009 (I.F=3.687).
  83. Papadokostopoulou A, Mathioudaki K, Scorilas A, Xynopoulos D, Ardavanis A, Kouroumalis E, Talieri M. Colon cancer and protein arginine methyltransferase 1 gene expression. Anticancer Res, 29(4):1361-6, 2009 (IF= 1.872).
  84. Thomadaki H, Scorilas A. Molecular profile of breast versus ovarian cancer cells in response to treatment with the anticancer drugs cisplatin, carboplatin, doxorubicin, etoposide and taxol. Biol Chem, 389(11):1427-34, 2008 (IF= 2.689).
  85. Kontos CK, Papadopoulos IN, Scorilas A. Quantitative expression analysis and prognostic significance of the novel apoptosis-related gene BCL2L12 in colon cancer. Biol Chem, 389(12):1467-75, 2008 (IF= 2.689).
  86. Thomadaki H, Karaliota A, Litos C, Scorilas A. Enhanced concentration-dependent cytotoxic effect of the dinuclear copper(II) complex of L-carnitine [Cu2(L-carnitine)2Cl2(H2O)2]Cl2, compared to L-carnitine or copper chloride dihydrate, in human leukemic cell lines. J Med Chem, 51(13):3713-9, 2008 (I.F=5.480).
  87. Mathioudaki K, Papadokostopoulou A, Scorilas A, Xynopoulos D, Agnanti N, Talieri M. The PRMT1 gene expression pattern in colon cancer. Br J Cancer, 16,99(12):2094-9,2008 (IF= 4.817).
  88. Kountourakis P, Psyrri A, Scorilas A, Camp R, Markakis S, Kowalski D, Diamandis EP, Dimopoulos MA. Prognostic value of kallikrein-related peptidase 6 protein expression levels in advanced ovarian cancer evaluated by automated quantitative analysis (AQUA). Cancer Sci, 99(11):2224-9, 2008 (I.F=3.534).
  89. Ardavanis A, Koumna S, Fragos I, Malliou S, Kyriakou F, Mantzaris I, Scorilas A, Rigatos G. Erlotinib monotherapy in patients with advanced non-small cell lung cancer: an effective approach with low toxicity. Anticancer Res, 28(4C):2409-15, 2008 (IF= 1.872).
  90. Ardavanis A, Kountourakis P, Kyriakou F, Malliou S, Mantzaris I, Garoufali A, Yiotis I, Scorilas A, Baziotis N, Rigatos G. Trastuzumab plus paclitaxel or docetaxel in HER-2-negative/HER-2 ECD-positive anthracycline- and taxane-refractory advanced breast cancer. Oncologist, 13 (4):361-9, 2008 (I.F=4.540).
  91. Psyrri A, Kountourakis P, Scorilas A, Markakis S, Camp R, Kowalski D, Diamandis EP, Dimopoulos MA. Human tissue kallikrein 7, a novel biomarker for advanced ovarian carcinoma using a novel in situ quantitative method of protein expression. Ann Oncol, 19(7):1271-7, 2008 (I.F= 6.578).
  92. Avgeris M, Koutalellis G, Fragoulis EG, Scorilas A. Expression Analysis and Clinical Utility of L-Dopa Decarboxylase (DDC) in Prostate Cancer. Clin Biochem, 41(14-15):1140-9, 2008 (I.F=2.229).
  93. Thomadaki H, Tsiapalis CM, Scorilas A. The effect of the polyadenylation inhibitor cordycepin on human Molt-4 and Daudi leukaemia and lymphoma cell lines. Cancer Chemother Pharmacol, 61(4):703-11, 2008 (I.F = 2.571).
  94. Gregorakis AK, Stefanakis S, Malovrouvas D, Petraki K, Gourgiotis D, Scorilas A. Total and free PSA kinetics in patients without prostate cancer undergoing radical cystoprostatectomy. Prostate, 68(7):759-65, 2008 (I.F=3.566).
  95. Pampalakis G, Scorilas A, Sotiropoulou G. Novel splice variants of prostate-specific antigen and applications in diagnosis of prostate cancer. Clin Biochem, 41(7-8):591-7, 2008 (I.F=2.229).
  96. Thomadaki H, Scorilas A, Tsiapalis CM, Havredaki M. The role of cordycepin in cancer treatment via induction or inhibition of apoptosis: implication of polyadenylation in a cell type specific manner. Cancer Chemother Pharmacol, 61(2):251-65, 2008 (I.F = 2.571).
  97. Garoufali A, Kyriakou F, Kountourakis P, Yioti I, Malliou S, Nikaki A, Kardara E, Frangos I, Koumna S, Baziotis N, Scorilas A, Ardavanis A. Extracellular domain of HER2: a useful marker for the initial workup and follow-up of HER2-positive breast cancer. J Buon.;13(3):409-13, 2008 (IF= 0.706).
  98. Thomadaki H, Scorilas A. Breast cancer cells response to the antineoplastic agents cisplatin, carboplatin, and doxorubicin at the mRNA expression levels of distinct apoptosis-related genes, including the new member, BCL2L12. Ann N Y Acad Sci, 1095:35-44, 2007 (I.F=4.313).
  99. Katsarou ME, Thomadaki H, Katsaros N and Scorilas A. Effect of bleomycin and cisplatin on the expression profile of SRA1, a novel member of pre-mRNA splicing factors, in HL-60 human promyelocytic leukemia cells. Biol Chem, 388(8):773-8, 2007 (IF= 2.689).
  100. Floros KV, Talieri M and Scorilas A. Topotecan and methotrexate alter expression of the apoptosis-related genes BCL2, FAS and BCL2L12 in leukemic HL-60 cells. Biol Chem, 387(12):1629-33,2007 (IF= 2.689).